A. He

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

M. Trojano, F. Grand'Maison, F. Piehl, 2020, The Lancet Neurology.

Hyperdense middle cerebral artery sign is associated with increased risk of hemorrhagic transformation after intravenous thrombolysis for patients with acute ischaemic stroke

B. Campbell, S. Davis, L. Churilov, 2013, Journal of Clinical Neuroscience.

Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden.

H. Gyllensten, J. Hillert, Alejandra Machado, 2022, Multiple sclerosis and related disorders.

Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy

S. Montoto, R. Marcus, K. Ardeshna, 2015, AIDS.

Every 15-Min Delay in Recanalization by Intra-Arterial Therapy in Acute Ischemic Stroke Increases Risk of Poor Outcome

L. Churilov, R. Dowling, B. Yan, 2015, International journal of stroke : official journal of the International Stroke Society.

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

J. Lechner-Scott, M. Trojano, F. Grand'Maison, 2015, JAMA neurology.

Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study

O. Ciccarelli, J. Hillert, T. Spelman, 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis

O. Ciccarelli, H. Butzkueven, J. Hillert, 2023, Multiple sclerosis.

Premorbid Sociodemographic Status and Multiple Sclerosis Outcomes in a Universal Health Care Context

O. Ciccarelli, A. Manouchehrinia, A. Glaser, 2023, JAMA Network Open.